

Curidium Medica plc (“Curidium” or the “Company”)

CURIDIUM TO PRESENT AT THE PERSONALISED MEDICINE 2008 CONFERENCE AND EPIC BIOTECH CONFERENCE

London, UK, [20] May 2008, Curidium Medica plc, (LSE: CUR) the personalized medicine company focused on bringing the right drug to the right patient, today announced that Dr. Anne Bruinvels, Founder and Chief Scientific Officer, will be presenting at the PharmaIQ’s Personalised Medicine 2008 in London on Thursday 22nd May at 14.00 local time at Café Royal, London.

Dr. Bruinvels will give a presentation entitled “Companion Diagnostics and Targeted Medicines”, and will be discussing PsychINDx™, Curidium’s blood diagnostic tool to sub-classify the schizophrenia and bipolar disorder patient population into different subgroups which may be applied to stratify and optimize clinical trials of new antipsychotic drug treatments.

Dr. Smita Price, Director of Psychiatry Research, will be presenting at the EPIC Biotech conference in London on Thursday 22nd May at 14.10 local time at the Cumberland Hotel, London. Dr. Price will present an overview of Curidium’s latest developments.

Ends

For further information, please contact:

Anne T. Bruinvels, PhD +44 (0)20 7383 5345
Founder & CSO, Curidium Medica plc

Rob Smith +44 (0)20 7383 5345
Finance Director, Curidium Medica plc

Charlie Cunningham +44 (0)20 7600 1658
JM Finn Capital Markets Ltd

Billy Clegg / Edward Westropp / Annie Evangelis + 44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

Curidium Medica plc

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium’s initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.
2. Improved therapies identified through novel drug targets.

3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc © 2001-2008. All rights reserved.
Studio 10, Tiger House, London WC1H 9BY, United Kingdom.
Email: info@curidium.com Tel.: +44 (0)20 7383 5345, Fax: +44 (0)20 7383 2973